2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Acura Nanomedicine Inc.

Biomedical EcoSystem development office in Taiwan, BEST

July 24th (Fri) 19:30 - 21:00 Entrepreneur Pitch 3

Acura Nanomedicine Inc.

Company Info

Name /Acura Nanomedicine Inc.

Address /2F., No. 12, Zhouzi St., Neihu Dist., Taipei City 114, Taiwan (R.O.C.)

Website /tw.acura-nanomed.com

Presenter

Name /Brian Hsu

Title /CEO

Email /d947624@gmail.com

Telephone /(Work) +886-2-26479488

Fax /

Mobile /+886-935-345748

Company Type

Biotechnology

About the Company

Acura Nanomedicine Inc. funded in July 2017. The scientific team of Acura Nanomed. is consist of Ph.Ds & Masters with multi-discipline backgrounds of biotech., medical science, chemical engineering, & nanotechnology. By integrating & applying multiple technologies, we have successfully developed the anti-cancer drug_AN-845 & it’s nano-formulation: Nano-845. AN-845 can completely block the growth of drug-resistant pancreatic cancer in vitro & in vivo without side effects. AN-845 also shows great potential to treat many different types of cancer and can development fallow 2 fast-track regulations(orphan drug & 505(b)2) simultaneously to minimize the development time & costs.

Brief Description of main products or services

  • Technology platforms:
    (1) High Efficiency Repurpose Drug Screening Platform
    (2) Joint Direct Active Modular-Nanovehicle Platform (NanoJDAMTM, NanoAcGelTM)
  • Products:
    (1) AN-845 (Oral administration):
    Anti-cancer drug-repurposing formula.
    Completely suppress drug-resistant pancreatic growth in vitro & in vivo without side effects.
    Show great potential to treat Hepatoma, Glioblasttoma(GBM)…etc.
    (2) Nano-845 (i.v. administration):
    Nano-formulation of AN-845, further increase therapeutic benefit.
    (3) AcGel-845: (i.t. administration):
    Design for AN-845 long-term slow releasing inside the tumor.

Contact Person

Name /Brian Hsu

Email /d947624@gmail.com

Phone /+886-935-345748